• Silo Wellness (SILO) is partnering with Oregon-based psilocybin producer, Satya
  • The companies plan to develop a robust ecosystem to support the well-being of Oregonian psilocybin patients and entrepreneurs alike
  • Pursuant to their two-year agreement, Satya has granted Silo a right of first refusal that guarantees Silo’s affiliates first rights to any of Satya’s psilocybin biomass
  • Founder and CEO, Mike Arnold, spoke with Shoran Devi about the news
  • Silo Wellness is a growth-oriented holding company focused on psychedelic opportunities
  • Silo Wellness (SILO) last traded at $0.015 per share

Silo Wellness (SILO) is partnering with Oregon-based psilocybin producer, Satya.

Satya offers licensed psilocybin products and services with a focus on solving mental-health challenges in Oregon. It announced a Portland-area psilocybin therapy center earlier this year.

The companies plan to develop a robust ecosystem to support the well-being of Oregonian psilocybin patients and entrepreneurs alike. Toward this end, they have established a raw materials supply and purchase agreement, including a right of first refusal (ROFR) that guarantees Silo’s affiliates first rights to any of Satya’s psilocybin biomass.

Under the agreement, Satya will provide 10 mg analyte psilocybin doses and 1 mg analyte psilocybin microdoses to any Silo affiliate properly licensed under Ballot Measure 109.

The buyer shall pay $50,000 in advance for the materials, which shall be credited against future purchases.

The agreement is for an initial two years terminating March 30, 2025, with a renewal for successive one-year periods.

Founder and CEO, Mike Arnold, spoke with Shoran Devi about the news.

Silo Wellness is a growth-oriented holding company focused on psychedelic opportunities. The company was founded in 2018 in Oregon and is headquartered in Toronto with a presence in Jamaica.

Silo Wellness (SILO) last traded at $0.015 per share.

This is sponsored content, please see full disclaimer here.


More From The Market Online
Image description: an AI generated photo with a stethoscope

WELL Health receives C$15.3 million in funding for AI healthtech

WELL Health Technologies (TSX:WELL) locks in C$15.3 million in funding for a project to develop artificial intelligence health technology.
Theratechnologies image of a lab technician handling samples

Theratechnologies stock jumps on positive income report

Theratechnologies stock (TSX:TH) opens nearly 4 per cent higher on Wednesday on the release of its latest financial results.